Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease. Their findings, demonstrated across cell cultures, preclinical models, and samples of human lung tissue, show that blocking Epac1 can slow the progression of the disease.
This article was originally published on MedicalXpress.com